{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"79.5","upperLimit":"93.9","value":"88.1"},{"groupId":"OG001","lowerLimit":"82.6","upperLimit":"95.9","value":"90.8"},{"groupId":"OG002","lowerLimit":"75.7","upperLimit":"91.5","value":"84.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"65"},{"groupId":"OG002","value":"66"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants who achieved partial response (PR) or better according to international myeloma working group (IMWG) criteria. IMWG criteria for PR: greater than or equal to (\\>=) 50 percent (%) reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>=90% or to less than (\\<) 200 milligrams (mg) per 24 hours, If the serum and urine M-protein are not measurable, a decrease of \\>=50% in the difference between involved and uninvolved free light chain (FLC) levels is required in place of the M-protein criteria, If serum and urine M-protein are not measurable, and serum free light assay is also not measurable, \\>=50% reduction in bone marrow plasma cells (PCs) is required in place of M-protein, provided baseline bone marrow plasma cell percentage was \\>=30%. In addition to the above criteria, if present at baseline, a \\>=50% reduction in the size of soft tissue plasmacytomas is also required.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received daratumumab 1800 mg by SC injection on Days 1, 8, 15, 22, 29 and 36 of Cycle 1, then on Days 1 and 22 in Cycles 2 to 9, and Day 1 of Cycle 10 and thereafter until documented progression of disease, unacceptable toxicity, or up to 2 years and 7 months; bortezomib 1.3 mg/m\\^2 SC injection on Day 1, 4, 8, 11, 22, 25, 29 and 32 of Cycle 1 and on Days 1, 8, 22 and 29 of Cycles 2 to 9; melphalan 9 mg/m\\^2 orally on Day 1 through Day 4 of Cycles 1 to 9; prednisone 60 mg/m\\^2 orally on Days 1 to 4 of cycles 1 to 9.","id":"OG000","title":"D + Bortezomib + Melphalan + Prednisone (D-VMP)"},{"description":"Participants received daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2, then on Day 1 and 15 of Cycles 3 to 6, and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or up to 2 years and 7 months; lenalidomide 25 mg orally on Day 1 through Day 21 of each cycle until documented progression of disease, unacceptable toxicity, or end of study and dexamethasone 40 mg orally or intravenously weekly until documented progression of disease, unacceptable toxicity, or up to 2 years and 7 months.","id":"OG001","title":"Daratumumab + Lenalidomide + Dexamethasone (D-Rd)"},{"description":"Participants received daratumumab 1800 mg by SC injection on Days 1, 8, 15 and 22 of Cycles 1 and 2 (each cycle is of 28 days), then on Day 1 and 15 of Cycles 3 to 6, and on Day 1 of Cycle 7 and thereafter until documented progression of disease, unacceptable toxicity, or up to 2 years and 7 months; Carfilzomib 20 mg/m\\^2 IV on Day 1 of Cycle 1 only, then 70 mg/m\\^2 IV on Days 8 and 15 of Cycle 1 and Days 1, 8 and 15 of Cycle 2 and thereafter until documented progression of disease, unacceptable toxicity, or up to 2 years and 7 months and dexamethasone 40 mg orally or IV weekly for Cycles 1-9, then on Days 1, 8, 15 of each cycle for Cycle 10 and thereafter until documented progression of disease, unacceptable toxicity, or up to 2 years and 7 months.","id":"OG002","title":"Daratumumab + Carfilzomib + Dexamethasone (D-Kd)"}],"paramType":"NUMBER","populationDescription":"All treated analysis set included all participants who have received at least 1 dose of study treatment. This primary outcome measure (OM) was planned to be analyzed for D-VMP, D-Rd and D-Kd cohorts only.","reportingStatus":"POSTED","timeFrame":"Up to 2 years 3 months","title":"D-VMP, D-Rd, and D-Kd Cohorts: Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}